News

A regular review of an FDA approval application is underway for the combination of pembrolizumab and standard chemotherapy for the treatment of advanced biliary tract cancer.

The FoundationOne®Liquid CDx has received FDA approval as a companion diagnostic for encorafenib plus cetuximab for patients with BRAF V600E-mutated metastatic colorectal cancer.

Results presented in a poster at the 2023 ASCO Annual Meeting demonstrated similar progression-free survival between acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia.

Experts say results from a phase 1 study of olverembatinib in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumor were encouraging and warrant further research.

Hope S. Rugo, MD, FASCO, discusses background and key findings from the phase 3 CAPItello-291 trial in breast cancer.

Treatment with INT230-6 alone led to extended survival among patients with soft tissue sarcoma by nearly 450 days, compared with synthetic controls, and demonstrated a favorable safety profile.

Now that the FDA has lifted the partial clinical hold on the phase 1 study of FHD-286 in patients with relapsed/refractory acute myelogenous leukemia and myelodysplastic syndrome, there are plans to initiate a trial to further assess the agent with decitabine or cytarabine.

In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.

Updated progression-free survival analysis data presented at the 2023 ASCO Annual Meeting favored the combination of nivolumab plus relatlimab in patients with melanoma.

At a median follow-up of 4.1 months, the overall response rate across all patients with advanced solid tumors treated with BL-B01D1 was 45.3%, according to data from a phase 1 study.

Ciltacabtagene autoleucel was recently said to be a new standard-of-care for relapsed or refractory multiple myeloma. Soon, it may be an FDA-approved therapy.

According to the developer, a future approval of dostarlimab for this indication would bring the first meaningful frontline treatment for this patient population in decades.

While the phase 2 CTEP-P9466 trial met its complete response end point, the trial missed its other co-primary end points in patients with BRAF V600–mutant metastatic melanoma.

In most key prespecified molecularly defined subsets of patients with pretreated KRAS G12C–mutated non–small cell lung cancer, sotorasib continued to demonstrate consistent benefit vs docetaxel.

In an interview with Targeted Oncology, Joshua K. Sabari, MD, discussed drug shortages and how they are affecting clinicians and patients in the oncology space.

Treatment with lisocabtagene maraleucel elicited encouraging responses and met the primary end point of the TRANSCEND CLL 004 trial in patients with relapsed/refractory CLL/SLL.

The phase 3 LUNAR trial evaluating tumor treating fields with standard-of-care therapies met its primary end point in patients with metastatic non–small cell lung cancer.

Data presented at the ASCO 2023 Annual Meeting showed that the addition of pembrolizumab to pemetrexed and platinum-based chemotherapy did not statistically improve survival in patients with TKI-resistant EGFR-mutated non–small cell lung cancer.

Lucia Masarova, MD, discusses available treatment options for patients with essential thrombocythemia.

The combination of avutometinib with defactinib elicited high activity in patients with recurrent low-grade serous ovarian cancer, according to data from RAMP 201.

Sara Tolaney, MD, MPH, discusses sacituzumab govitecan-hziy as an effective and safe treatment for patients with hormone receptor-positive/HER2-negative metastatic breast cancer.

Responses to fam-trastuzumab deruxtecan-nxki in patients with HER2-expressing tumors were durable in the phase 2 DESTINY-PanTumor02 trial.

A subgroup analysis from the EMERALD trial reveals that elacestrant prolonged progression-free survival for certain patients with estrogen receptor-positive HER2-negative non-detected shortly after progression on CDK3/6 inhibitors.

Katherine B. Peters, MD, PhD, discusses the findings from the phase 3 INDIGO trial which were presented at the 2023 ASCO annual meeting.

The FDA is no longer concerned about the safety of MT-0169, and the developer of the agent plans to focus its effort on the extramedullary myeloma population.

Manmeet Ahluwalia, MD, discusses results from the CRUX trial which were presented during the 2023 American Society of Clinical Oncology Annual Meeting.

In an interview with Targeted Oncology, Narissa Nonzee, PhD, discussed a study which focused on increasing colorectal screening rates among patients in ethnic minority communities.

Marc S. Ernstoff, MD, provides recommendations for managing patients with metastatic melanoma.

Lurbinectedin yielded a value of 6.52 nM on the key pharmacological efficacy variable IC50, according to a poster presented at the 2023 Annual Meeting of the American Association for Cancer Research

Results from the phase 2 MAJIC-PV study showed that patients with polycythemia vera who are intolerant to hydroxycarbamide chemotherapy had superior efficacy results on ruxolitinib.